当前位置： SCI文献检索 > ALIMENTARY PHARMACOLOGY & THERAPEUTICS期刊下所有文献 > Review: clinical trials in peptic ulcer disease--problems of methodology and interpretation.

Review: clinical trials in peptic ulcer disease--problems of methodology and interpretation.

Abstract：

:This review focuses on the methodology and interpretation of drug trials in peptic ulcer disease. The problems of planning and conduct that are discussed include the ethics of using placebo, eligibility criteria, estimations of sample size, stopping rules, randomization, blinding, and efficacy criteria, that is, ulcer healing and pain relief in the short term and prevention of relapse and complications in the long term. Statistical topics covered include confidence intervals, evaluation of survival type data, post-stratification, and sub-group analysis. The difference between clinical and statistical significance is discussed, major problems being overemphasis on P-value, type II errors, and post hoc power determinations. Explanatory and pragmatic questions are based on compliance-to-protocol and intention-to-treat cohorts, respectively, and involve problems of compliance testing, evaluation of withdrawals, and the use of fixed-dose regimens. The rather slow process for clinical trials to gain acceptance is described, and it is proposed to rely on disease-related and behavioural barriers, lack of knowledge of the inherent limitations of methodology, and overemphasis on the subject of peptic ulcer healing, in addition to some concern at the relevance of assessing long-term drug intervention by repeated endoscopies rather than by studying symptoms and the incidence of complications. We foresee an increased impact of clinical trials on ulcer research and therapeutic decision making, provided physicians are able to develop the proper methodology to answer the relevant questions.

journal_name

Aliment Pharmacol Ther

journal_title

Alimentary pharmacology & therapeutics

authors

Lauritsen K,Rask-Madsen J

doi

10.1111/j.1365-2036.1987.tb00610.x

subject

Has Abstract

pub_date

1987-04-01 00:00:00

pages

91-123

issue

2

eissn

0269-2813

issn

1365-2036

journal_volume

1

pub_type

杂志文章,评审

相关文献

ALIMENTARY PHARMACOLOGY & THERAPEUTICS文献大全
  • Review article: the screening, diagnosis and optimal management of haemochromatosis.

    abstract：:Haemochromatosis was first recognized as a disease entity over a century ago and its hereditary nature recognized over 60 years ago. However it was only in late 1996 that the haemochromatosis gene was cloned and a single C282Y mutation confirmed as being the cause of all HLA-linked iron overload in Caucasian populatio...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.1997.00197.x

    authors： George DK,Powell LW

    更新日期：1997-08-01 00:00:00

  • Review article: The diagnosis of coeliac disease.

    abstract：:Coeliac disease is a chronic inflammatory condition associated with small intestinal injury that results in the malabsorption of different nutrients. The damaging factor is gluten present in wheat, barley and rye. The diagnosis relies on the clinical picture of the patient, serological markers for coeliac disease, cha...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2003.01442.x

    authors： Abdulkarim AS,Murray JA

    更新日期：2003-04-01 00:00:00

  • Review article: 'true' re-infection of Helicobacter pylori after successful eradication--worldwide annual rates, risk factors and clinical implications.

    abstract：BACKGROUND:The incidence of 'true' re-infection with Helicobacter pylori after successful eradication remains uncertain. AIM:To determine the worldwide rates, risk factors and clinical implications of 'true' re-infection of Helicobacter pylori. 'True' re-infection of H. pylori is defined as the situation where tests f...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2008.03873.x

    authors： Zhang YY,Xia HH,Zhuang ZH,Zhong J

    更新日期：2009-01-01 00:00:00

  • Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data.

    abstract：BACKGROUND:Limited therapeutic options exist for severe gastroparesis, where severe nausea and vomiting can lead to weight loss, dehydration and malnutrition due to inadequate caloric and fluid intake. TZP-101 (ulimorelin) is a ghrelin receptor agonist that accelerates gastric emptying and improves upper gastrointestin...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2010.04567.x

    authors： Wo JM,Ejskjaer N,Hellström PM,Malik RA,Pezzullo JC,Shaughnessy L,Charlton P,Kosutic G,McCallum RW

    更新日期：2011-03-01 00:00:00

  • Effects on the rat oxyntic mucosa of the histamine2-antagonist loxtidine and the H+, K(+)-ATPase inhibitor omeprazole.

    abstract：:The present study examined whether histamine could affect the growth of the enterochromaffin-like (ECL) cell and the parietal cell. The effects of the unsurmountable histamine H2-receptor antagonist loxtidine (80 mg/kg) and the H+, K(+)-ATPase inhibitor omeprazole (100 mumol/kg) were compared in female Sprague-Dawley ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.1992.tb00055.x

    authors： Brenna E,Waldum HL,Sandvik AK,Schulze Søgnen B,Kristensen A

    更新日期：1992-06-01 00:00:00

  • Gastric carcinoids after long-term use of a proton pump inhibitor.

    abstract：BACKGROUND:Proton pump inhibitors (PPIs) are potent inhibitors of gastric acid secretion and give hypergastrinemia secondary to gastric hypoacidity. PPI treatment therefore induces enterochromaffin-like (ECL) cell hyperplasia. Long-term hypergastrinemia in rodents and man also leads to ECL cell neoplasia. Whether long-...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12012

    authors： Jianu CS,Fossmark R,Viset T,Qvigstad G,Sørdal O,Mårvik R,Waldum HL

    更新日期：2012-10-01 00:00:00

  • Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.

    abstract：BACKGROUND:Factors associated with mortality and disease progression in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are poorly understood. AIMS:To assess the impact of liver disease severity, demographics and comorbidities on all-cause mortality and liver disease progression in a...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.16016

    authors： Canbay A,Kachru N,Haas JS,Sowa JP,Meise D,Ozbay AB

    更新日期：2020-10-01 00:00:00

  • Stepwise diagnosis in covert hepatic encephalopathy: critical flicker frequency and MELD-score as a first-step approach.

    abstract：BACKGROUND:The diagnosis of covert hepatic encephalopathy (CHE) by means of portosystemic encephalopathy syndrome (PSE) test is costly and therefore infrequently performed. AIM:To determine the ability of critical flicker frequency (CFF) alone or in combination with laboratory findings, as an initial test to pre-selec...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13721

    authors： Greinert R,Ripoll C,Hollenbach M,Zipprich A

    更新日期：2016-09-01 00:00:00

  • Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.

    abstract：BACKGROUND:Patients with thalassaemia major depend on blood transfusions. In Italy, up to 80% of thalassaemia patients bear HCV antibodies due to HCV contaminated transfusions before 1990. Thalassaemia patients with HCV infection have high risk of developing HCC. Treatment based on Pegylated-IFN (Peg-IFN) and Ribavirin...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/apt.14197

    authors： Mangia A,Sarli R,Gamberini R,Piga A,Cenderello G,Piazzolla V,Santoro R,Caruso V,Quarta A,Ganga R,Copetti M,Forni G

    更新日期：2017-08-01 00:00:00

  • Systematic review: epidemiology of hepatitis C genotype 6 and its management.

    abstract：BACKGROUND:Hepatitis C virus (HCV) genotype 6 is common among patients from Southeast Asia and the surrounding regions, where HCV prevalence is also high. HCV genotype 6 has great genetic diversity and different response to antiviral therapy compared with the more commonly known genotype 1. AIM:Our goal was to provide...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2011.04714.x

    authors： Chao DT,Abe K,Nguyen MH

    更新日期：2011-08-01 00:00:00

  • Obesity is independently associated with infection in hospitalised patients with end-stage liver disease.

    abstract：BACKGROUND:Infection is the most common cause of mortality in end-stage liver disease (ESLD). The impact of obesity on infection risk in ESLD is not established. AIM:To characterise the impact of obesity on infection risk in ESLD. METHODS:We evaluated the association between infection and obesity in patients with ESL...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13426

    authors： Sundaram V,Kaung A,Rajaram A,Lu SC,Tran TT,Nissen NN,Klein AS,Jalan R,Charlton MR,Jeon CY

    更新日期：2015-12-01 00:00:00

  • Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis.

    abstract：BACKGROUND:This randomized, double-blind, multicentre study compared lansoprazole with placebo for symptomatic relief of patients with non-erosive gastro-oesophageal reflux disease (GERD). METHODS:214 patients with symptomatic, non-erosive GERD (moderate to severe daytime and/or night-time heartburn greater than half ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1046/j.1365-2036.1999.00558.x

    authors： Richter JE,Kovacs TO,Greski-Rose PA,Huang section sign B,Fisher R

    更新日期：1999-06-01 00:00:00

  • Hepatitis E virus in patients with decompensated chronic liver disease: a prospective UK/French study.

    abstract：BACKGROUND:In developed countries, hepatitis E is a porcine zoonosis caused by hepatitis E virus (HEV) genotype 3. In developing countries, hepatitis E is mainly caused by genotype 1, and causes increased mortality in patients with pre-existing chronic liver disease (CLD). AIM:To determine the role of HEV in patients ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13309

    authors： Blasco-Perrin H,Madden RG,Stanley A,Crossan C,Hunter JG,Vine L,Lane K,Devooght-Johnson N,Mclaughlin C,Petrik J,Stableforth B,Hussaini H,Phillips M,Mansuy JM,Forrest E,Izopet J,Blatchford O,Scobie L,Peron JM,Dalton H

    更新日期：2015-09-01 00:00:00

  • A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.

    abstract：BACKGROUND:Sulfasalazine is accepted therapy for active ulcerative colitis, but side-effects and intolerance are common. Balsalazide is an azo-bonded pro-drug which also releases 5-aminosalicylic acid into the colon, but uses an inert carrier molecule. AIM:To compare the safety and efficacy of sul- fasalazine, 3 g, wi...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1046/j.1365-2036.2002.01151.x

    authors： Mansfield JC,Giaffer MH,Cann PA,McKenna D,Thornton PC,Holdsworth CD

    更新日期：2002-01-01 00:00:00

  • Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects.

    abstract：BACKGROUND:Omeprazole has become available in a tablet formulation, a Multiple Unit Pellet System (MUPS) containing a large number of small individually enteric-coated micropellets. AIM:To compare the acid-inhibitory effect of omeprazole MUPS 20 mg with pantoprazole 40 mg and to describe the pharmacokinetics of both d...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1046/j.1365-2036.2000.00806.x

    authors： Geus WP,Mathôt RA,Mulder PG,Lamers CB

    更新日期：2000-08-01 00:00:00

  • Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection.

    abstract：BACKGROUND:Hepatitis B (HBV)-infected patients have a higher morbidity and mortality when super-infected by hepatitis A (HAV). AIM:To evaluate the immunogenicity and safety of a commercial inactivated HAV vaccine in Chinese patients with chronic HBV infection. METHODS:Sixty-five HBV-infected patients (30 carriers, 22...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1046/j.1365-2036.1999.00628.x

    authors： Tsang SW,Sung JJ

    更新日期：1999-11-01 00:00:00

  • Age-dependent eradication of Helicobacter pylori with dual therapy.

    abstract：BACKGROUND:Combined treatment using an acid-inhibiting drug with antibiotics can cure Helicobacter pylori infection. However, eradication rates are highly variable, especially if a proton pump inhibitor is used with amoxycillin. Therefore it is important to define factors/predictors of the clinical outcome. METHODS:In...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.1997.00210.x

    authors： Treiber G,Ammon S,Klotz U

    更新日期：1997-08-01 00:00:00

  • Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.

    abstract：BACKGROUND:Five oral nucleos(t)ide analogues are available to treat chronic hepatitis B (CHB). With the availability of newer agents, their efficacy on incidence of hepatocellular carcinoma (HCC) is not well described. AIM:To determine the efficacy of oral anti-viral agents in reducing HCC risk in relationship with ot...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,meta分析

    doi：10.1111/apt.12344

    authors： Singal AK,Salameh H,Kuo YF,Fontana RJ

    更新日期：2013-07-01 00:00:00

  • Review article: the management of hepatocellular carcinoma.

    abstract：BACKGROUND:Hepatocellular carcinoma is the leading cause of death in cirrhosis. A majority of patients present at an advanced stage with poor prognosis. AIM:To review the current screening, diagnosis and management strategies involved in hepatocellular carcinoma. METHODS:A literature search was performed using PubMed...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2009.04200.x

    authors： Cabrera R,Nelson DR

    更新日期：2010-02-15 00:00:00

  • The impact of hepatitis C burden: an evidence-based approach.

    abstract：BACKGROUND:Infection with the hepatitis C virus (HCV) has been considered a major cause of mortality, morbidity and resource utilisation in the US. In addition, HCV is the main cause of hepatocellular cancer (HCC) in the US. Recent developments in the diagnosis and treatment of HCV, including new recommendations pertai...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12625

    authors： Younossi ZM,Kanwal F,Saab S,Brown KA,El-Serag HB,Kim WR,Ahmed A,Kugelmas M,Gordon SC

    更新日期：2014-03-01 00:00:00

  • Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study.

    abstract：BACKGROUND:There is no consensus on the standard treatment of gastric mucosa-associated lymphoid tissue (MALT) lymphoma for Helicobacter pylori-negative patients and for patients with persistent disease despite H. pylori eradication. AIM:To evaluate the comparative efficacy and safety of alkylating agents and rituxima...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12635

    authors： Amiot A,Lévy M,Copie-Bergman C,Dupuis J,Szablewski V,Le Baleur Y,Baia M,Belhadj K,Sobhani I,Leroy K,Haioun C,Delchier JC

    更新日期：2014-03-01 00:00:00

  • Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.

    abstract：BACKGROUND:The widespread use of eradication therapy for Helicobacter pylori in Japan has led to an increase in antibiotic-resistant strains and the problem of re-treatment in cases of eradication failure. AIM:To perform drug sensitivity testing for metronidazole in 92 H. pylori-positive patients who had failed eradic...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2003.01401.x

    authors： Murakami K,Sato R,Okimoto T,Nasu M,Fujioka T,Kodama M,Kagawa J

    更新日期：2003-01-01 00:00:00

  • Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH.

    abstract：BACKGROUND:Treatment with a continuous i.v. proton pump inhibitor is presumed to promote clot formation and stability by sustaining intragastric pH > or = 6. AIM:We postulated that very frequent oral dosing of proton pump inhibitors should simulate i.v. infusion and achieve similar pH control. METHODS:Twenty healthy ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2006.02933.x

    authors： Pais SA,Nathwani RA,Dhar V,Nowain A,Laine L

    更新日期：2006-06-01 00:00:00

  • Review article: the incidence and risk factors for irritable bowel syndrome in population-based studies.

    abstract：BACKGROUND:In the absence of prior gastrointestinal infection, the risk factors for irritable bowel syndrome (IBS) are not well established. AIM:To identify the incidence and risk factors for IBS in general population samples METHODS: Narrative review of population-based studies. Electronic databases were searched usi...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.15396

    authors： Creed F

    更新日期：2019-09-01 00:00:00

  • PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome.

    abstract：BACKGROUND:The rs738409 GG variant in patatin-like phospholipase 3 (PNPLA3) is associated with non-alcoholic fatty liver disease (NAFLD) and disease severity. However, it remains unclear if it contributes to the development of NAFLD through affecting dietary pattern. AIM:To examine the association among PNPLA3 gene po...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12609

    authors： Shen J,Wong GL,Chan HL,Chan HY,Yeung DK,Chan RS,Chim AM,Chan AW,Choi PC,Woo J,Chu WC,Wong VW

    更新日期：2014-03-01 00:00:00

  • Coeliac disease: a biopsy is not always necessary for diagnosis.

    abstract：BACKGROUND:In view of the high diagnostic accuracy of immunoglobulin-A-tissue transglutaminase antibodies for detecting coeliac disease, we have explored whether a small bowel biopsy is always required to establish the diagnosis. AIM:To define the transglutaminase antibody level giving a positive predictive value for ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03609.x

    authors： Hill PG,Holmes GK

    更新日期：2008-04-01 00:00:00

  • Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study.

    abstract：BACKGROUND:Vitamin D has immune-regulatory functions in experimental colitis, and low vitamin D levels are present in Crohn's disease. AIM:To assess the effectiveness of vitamin D3 treatment in Crohn's disease with regard to improved disease course. METHODS:We performed a randomized double-blind placebo-controlled tr...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2010.04355.x

    authors： Jørgensen SP,Agnholt J,Glerup H,Lyhne S,Villadsen GE,Hvas CL,Bartels LE,Kelsen J,Christensen LA,Dahlerup JF

    更新日期：2010-08-01 00:00:00

  • General principles to enhance practice patterns in gastrointestinal endoscopy.

    abstract：AIM:To develop general rules on how to pursue a therapeutic goal of interventional endoscopy without getting lost in abundant details. METHODS:The influences of various medical interventions on the survival of a patient with gastrointestinal haemorrhage are modelled by an influence diagram. Survival is the focal point...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2002.01233.x

    authors： Sonnenberg A,Gavin MW

    更新日期：2002-05-01 00:00:00

  • Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Pantoprazole-Duodenal Ulcer-Study Group.

    abstract：BACKGROUND:Pantoprazole is a new substituted benzimidazole that blocks the H+/K(+)-ATPase in the gastric mucosa and thus inhibits acid secretion. METHODS:Efficacy and tolerability of pantoprazole (40 mg at breakfast) and ranitidine (300 mg at bedtime) in the treatment of uncomplicated acute duodenal ulcer were compare...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.1994.tb00163.x

    authors： Judmaier G,Koelz HR

    更新日期：1994-02-01 00:00:00

  • Effects of lactulose and polyethylene glycol on colonic transit.

    abstract：BACKGROUND:The effects of lactulose and polyethylene glycol on colonic transit are poorly established. AIM:To assess the effects of these laxatives on colonic transit in normal subjects. METHODS:Colonic transit (mean residence time, cumulative counts in stool, counts remaining in the proximal or distal colon) was mea...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1111/j.1365-2036.2005.02244.x

    authors： Fritz E,Hammer HF,Lipp RW,Högenauer C,Stauber R,Hammer J

    更新日期：2005-02-01 00:00:00